{"type":"trials","record":{"id":41665,"source_id":"clinicaltrials-gov","external_id":"NCT05170048","title":"Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD","brief_summary":"This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD). Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are: 1. AREDS2 supplements (Control Group, N=30) 2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)","overall_status":"Not Yet Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Evergreen Therapeutics, Inc.","enrollment":90,"countries":[],"start_date":"2026-06-01","completion_date":"2028-06-01","last_update_date":"2025-12-08","source_url":"https://clinicaltrials.gov/study/NCT05170048","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 75 Years","comparator":"Control Arm: AREDS2 supplements (SOC)","organization":"Evergreen Therapeutics, Inc.","interventions":["EG-301","AREDS2 supplements"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Adverse Events Assessment using CTCAE v5.0 — Evaluation in 26 weeks treatment period, and 4 weeks safety follow up peri…","GA lesion size change — From baseline to Week 26 treatment period","Overall retinal sensitivity — From baseline to Week 26 treatment period","BCVA in number of letters — From baseline to Week 26 treatment period, and 4 weeks safety follow up period.","Low luminance visual acuity (LLVA) — From baseline to Week 26 treatment period","Binocular reading speed — From baseline to Week 26 treatment period","Binocular critical print size — From baseline to Week 26 treatment period","NEI-VFQ score — From baseline to Week 26 treatment period","Plasma levels of bioactive lipids — From baseline to Week 26 treatment period","Plasma levels of beclin-1 levels — From baseline to Week 26 treatment period","Complement factor levels — From baseline to Week 26 treatment period"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)","EG-301","AREDS2 supplements"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05170048","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-06-01 to 2028-06-01","comparator":"Control Arm: AREDS2 supplements (SOC)","confidence":"structured-source","population":"ALL · 50 Years to 75 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.850Z","intervention":["EG-301","AREDS2 supplements"],"participants":90,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Adverse Events Assessment using CTCAE v5.0 — Evaluation in 26 weeks treatment period, and 4 weeks safety follow up peri…","GA lesion size change — From baseline to Week 26 treatment period","Overall retinal sensitivity — From baseline to Week 26 treatment period","BCVA in number of letters — From baseline to Week 26 treatment period, and 4 weeks safety follow up period.","Low luminance visual acuity (LLVA) — From baseline to Week 26 treatment period","Binocular reading speed — From baseline to Week 26 treatment period","Binocular critical print size — From baseline to Week 26 treatment period","NEI-VFQ score — From baseline to Week 26 treatment period","Plasma levels of bioactive lipids — From baseline to Week 26 treatment period","Plasma levels of beclin-1 levels — From baseline to Week 26 treatment period","Complement factor levels — From baseline to Week 26 treatment period"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41665","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}